Rx Product News: April 2023
sage-10k_20181231.htm
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
SEC Filing | Sage Therapeutics, Inc.
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
Jorge Luna on LinkedIn: So proud of my amazing team who won the Sage Therapeutics 2019 Field… | 59 comments
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Small Clinical Trials Lead To Big Results
Bipolar Depression: How do we treat it?
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage surges after depression drug gets rapid path to approval - PMLiVE
Biogen signs deal with Sage to develop depression, tremor therapies
